FDA approves UCB's Briviact to treat partial onset seizures

The US Food and Drug Administration yesterday approved Briviact (brivaracetam), from Belgium’s UCB (Euronext Brussels: UCB), as an add-on treatment to other medications to treat partial onset seizures in patients aged 16 years and older with epilepsy.

"Patients can have different responses to the various seizure medicines that are available," said Billy Dunn, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, adding: "With the approval of Briviact, I am pleased that patients with epilepsy have a new treatment option."

DEA classification awaited